Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Physiol Rep ; 6(3)2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29388342

RESUMO

The endogenous peroxisome proliferator-activated receptor alpha (PPAR-α) agonist Oleoylethanolamide (OEA) inhibits eating in rodents, mainly by delaying the onset of meals. The underlying mechanisms of OEA-induced anorexia, however, remain unclear. Animals treated with high OEA doses were shown to display signs of discomfort and impaired locomotion. Therefore, we first examined whether the impaired locomotion may contribute to OEA's anorectic effect. Second, it is controversial whether abdominal vagal afferents are necessary for OEA's anorectic effect. Thus, we explored alternative peripheral neural pathways mediating IP OEA's anorectic effect by performing a celiac-superior mesenteric ganglionectomy (CGX) or a subdiaphragmatic vagal deafferentation (SDA) alone or in combination. Exogenously administered OEA at a commonly used dose (10 mg/kg BW, IP) concurrently reduced food intake and compromised locomotor activity. Attempts to dissociate both phenomena using the dopamine D2/D3 receptor agonist Quinpirole (1 mg/kg BW, SC) failed because Quinpirole antagonized both, OEA-induced locomotor impairment and delay in eating onset. CGX attenuated the prolongation of the latency to eat by IP OEA, but neither SDA nor CGX prevented IP OEA-induced locomotor impairment. Our results indicate that IP OEA's anorectic effect may be secondary to impaired locomotion rather than due to physiological satiety. They further confirm that vagal afferents do not mediate exogenous OEA's anorectic effects, but suggest a role for spinal afferents in addition to an alternative, nonneuronal signaling route.


Assuntos
Anorexia/fisiopatologia , Endocanabinoides/farmacologia , Locomoção , Ácidos Oleicos/farmacologia , Animais , Anorexia/etiologia , Ingestão de Alimentos/efeitos dos fármacos , Endocanabinoides/toxicidade , Masculino , Ácidos Oleicos/toxicidade , Ratos , Ratos Sprague-Dawley , Nervo Vago/fisiologia
2.
Org Lett ; 19(10): 2510-2513, 2017 05 19.
Artigo em Inglês | MEDLINE | ID: mdl-28459595

RESUMO

Peptides are important in the drug discovery process. In analogy to nonpeptidic small-molecule counterparts, they can sometimes suffer from disadvantages such as their low bioavailability and poor metabolic stability. Herein, we report the synthesis of new oxetanyl dipeptides and their incorporation into Leu-enkephalin analogues as proof-of-principle studies. The modular approach that is described enables the incorporation of a variety of oxetanyl amino acids into potential peptide therapeutics.


Assuntos
Aminoácidos/química , Dipeptídeos , Encefalina Leucina , Estrutura Molecular , Peptidomiméticos
3.
ChemMedChem ; 10(3): 461-9, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25630804

RESUMO

The tert-butyl group is a common motif in medicinal chemistry. Its incorporation into bioactive compounds is often accompanied by unwanted property modulation, such as increased lipophilicity and decreased metabolic stability. Several alternative substituents are available for the drug discovery process. Herein, physicochemical data of two series of drug analogues of bosentan and vercirnon are documented as part of a comparative study of tert-butyl, pentafluorosulfanyl, trifluoromethyl, bicyclo[1.1.1]pentanyl, and cyclopropyl-trifluoromethyl substituents.


Assuntos
Butanos/química , Butanos/farmacocinética , Descoberta de Drogas , Butanos/farmacologia , Halogenação , Humanos , Metilação , Relação Estrutura-Atividade , Compostos de Enxofre/química , Compostos de Enxofre/farmacocinética , Compostos de Enxofre/farmacologia
4.
Appl Environ Microbiol ; 76(11): 3462-6, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20363793

RESUMO

Metabolic engineering of cyanobacteria has the advantage that sunlight and CO(2) are the sole source of energy and carbon for these organisms. However, as photoautotrophs, cyanobacteria generally lack transporters to move hydrophilic primary metabolites across membranes. To address whether cyanobacteria could be engineered to produce and secrete organic primary metabolites, Synechococcus elongatus PCC7942 was engineered to express genes encoding an invertase and a glucose facilitator, which mediated secretion of glucose and fructose. Similarly, expression of lactate dehydrogenase- and lactate transporter-encoding genes allowed lactate accumulation in the extracellular medium. Expression of the relevant transporter was essential for secretion. Production of these molecules was further improved by expression of additional heterologous enzymes. Sugars secreted by the engineered cyanobacteria could be used to support Escherichia coli growth in the absence of additional nutrient sources. These results indicate that cyanobacteria can be engineered to produce and secrete high-value hydrophilic products.


Assuntos
Proteínas de Membrana Transportadoras/genética , Proteínas de Membrana Transportadoras/metabolismo , Compostos Orgânicos/química , Compostos Orgânicos/metabolismo , Synechococcus/genética , Synechococcus/metabolismo , Proteínas de Bactérias/genética , Proteínas de Bactérias/metabolismo , Transporte Biológico , DNA Bacteriano/química , DNA Bacteriano/genética , Escherichia coli/crescimento & desenvolvimento , Escherichia coli/metabolismo , Frutose/metabolismo , Engenharia Genética , Glucose/metabolismo , Dados de Sequência Molecular , Análise de Sequência de DNA
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA